Task 2 AAV-K55-GRD-C24 efficacy (double dose, single time point) Body Weight.pptx

syn70747581

Created By Karis Weisgerber karisweisgerber

Id: 05439d40-6f8e-494a-ac3b-8e225ac7bb7d
sex: Female
assay: survival
organ: nerves
species: Mus musculus (humanized)
studyId: syn31821155
dataType: physiology parameter
entityId: syn70747581
Component: ClinicalAssayTemplate
diagnosis: Neurofibromatosis type 1
studyName: NTAP NF1 Gene Replacement Initiative- Development of a gene replacement therapy for cutaneous neurofibromas related to NF1
tumorType: Plexiform Neurofibroma
fileFormat: powerpoint
initiative: Gene Replacement Initiative
dataSubtype: processed
compoundDose: 1
compoundName: AAV9-GRD-C24
individualID: A766 A767 A 768 A769 A770 #1771 #1772 #1773 #1776 #1775 #1767 #1768 #1774 #1831 #1832 #1833 #1834 #1835 #1846 #1847 #1848 #1849 #1850
resourceType: result
fundingAgency: NTAP
timepointUnit: weeks
compoundDoseUnit: 1000000000000.0
experimentalCondition: One dosage 1e12 AAV9-GRD-C24 or 1e12 K55-GRD-C24 through tail vein, 5 mg/kg desamethasone every other day from Day 1.

Task 2 AAV-K55-GRD-C24 efficacy (double dose, single time point) Body Weight.pptx page is loading…